Athero-Flux consortium consists of eleven partners from nine EU countries (UK, Denmark, Finland, Germany, Italy, Sweden, Greece, France and Israel)
OBJECTIVES
Athero-Flux aims to identify, characterise and validate novel therapeutic targets for CVD by dissecting the biosynthesis and pro-atherogenic potential of specific molecular species of SLs identified by lipidomics as strong predictors of CV risk in large-scale clinical studies.
Specific objectives:
Objective 1: To identify the steps regulating the generation and signalling of specific SLs relevant to CV risk
Objective 2: To validate therapeutic targets in SL metabolism and downstream signalling using atherosclerosis models in vitro and in vivo
Objective 3: To develop clinically applicable LNA-based therapeutics for the treatment of CVD and its acute complications
Our team
-
Claudia Monaco
Professor of Cardiovascular Inflammation
-
Sir Marc Feldmann FRS
Emeritus Professor
-
Natacha Zanin
Postdoctoral Researcher
